Table 2.
Details of the antiplatelet and anticoagulant therapies
| n = 149 | (%) | ||
|---|---|---|---|
| Single | Antiplatelet | ||
| Aspirin | 65 | (43.6) | |
| Cilostazol | 7 | (4.7) | |
| Clopidogrel | 5 | (3.4) | |
| Ticlopidine | 3 | (2.0) | |
| Total | 80 | (53.7) | |
| Anticoagulant | |||
| Warfarin | 25 | (16.8) | |
| Rivaroxaban | 4 | (2.7) | |
| Dabigatran | 4 | (2.7) | |
| Apixaban | 1 | (0.7) | |
| Total | 34 | (22.8) | |
| Dual | Dual antiplatelet therapy | ||
| Aspirin + Clopidogrel | 14 | (9.4) | |
| Aspirin + Ticlopidine | 3 | (2.0) | |
| Aspirin + Cilostazol | 2 | (1.3) | |
| Total | 19 | (12.8) | |
| Antiplatelet + Anticoagulant | |||
| Aspirin + Warfarin | 10 | (6.7) | |
| Other combinations | 6 | (4.0) | |
| Total | 16 | (10.7) | |